LBA 18: Improvement in Survival with the Addition of Talazoparib to First-Line Enzalutamide Treatment in RR-Deficient mCRPC Patients
The TALAPRO-2 study showed a significant improvement in overall survival in men with mCRPC treated with the combination of talazoparib and enzalutamide, regardless of whether they had HRR gene alterations. In this sub-analysis, men without HRR-deficient cancers or with unknown HRR status had a modest clinical benefit.
Få tillgång
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.
- Få tillgång
- Om du redan har en profil: Logga in
